108 related articles for article (PubMed ID: 2943125)
21. New antitumor antibiotics: 13-methylaclacinomycin A and its derivatives.
Soga K; Furusho H; Mori S; Oki T
J Antibiot (Tokyo); 1981 Jun; 34(6):770-3. PubMed ID: 6944303
[No Abstract] [Full Text] [Related]
22. Cellular pharmacokinetics of aclacinomycin A in cultured L1210 cells. Comparison with daunorubicin and doxorubicin.
Zenebergh A; Baurain R; Trouet A
Cancer Chemother Pharmacol; 1982; 8(2):243-9. PubMed ID: 6955072
[TBL] [Abstract][Full Text] [Related]
23. Anthracycline antibiotic 2-hydroxyaclacinomycins. II. Production of 2-hydroxyaclacinomycins A and B by a new recombinant strain and their antitumor activities.
Yoshimoto A; Johdo O; Ishikura T; Takeuchi T
Jpn J Antibiot; 1991 Mar; 44(3):277-86. PubMed ID: 1880910
[TBL] [Abstract][Full Text] [Related]
24. Enhanced activity of mouse peritoneal cells after aclacinomycin administration.
Cuellar AB; Algara DS; Metzger G; Orbach-Arbouys S
Cancer Res; 1987 Jul; 47(13):3477-84. PubMed ID: 3034418
[TBL] [Abstract][Full Text] [Related]
25. Reduction and hydrolysis of 2-hydroxyaclacinomycin A.
Matsuzawa Y; Oki T
J Antibiot (Tokyo); 1981 Nov; 34(11):1495-7. PubMed ID: 7319910
[No Abstract] [Full Text] [Related]
26. Enhancement of immune responses and possible inhibition of suppressor cells by aclacinomycin A.
Ishizuka M; Takeuchi T; Masuda T; Fukasawa S; Umezawa H
J Antibiot (Tokyo); 1981 Mar; 34(3):331-40. PubMed ID: 6456249
[TBL] [Abstract][Full Text] [Related]
27. Failure of aclacinomycin and 7-con-O-methylnogarol (7-OMEN) to decrease cardiac guanylate cyclase activity.
Levey BA; Ruiz E; Rogerson B; Lehotay DC; Levey GS
Cancer Treat Rep; 1980; 64(10-11):1127-8. PubMed ID: 6109566
[No Abstract] [Full Text] [Related]
28. Lethal effect of aclacinomycin A on cultured mouse L cells.
Tanabe M; Miyamoto T; Nakajima Y; Terasima T
Gan; 1980 Oct; 71(5):699-703. PubMed ID: 6939647
[TBL] [Abstract][Full Text] [Related]
29. Antitumor efficacies of aclacinomycin A by oral administration.
Tsukagoshi S; Tsuruo T; Yamori T; Iida H; Naganuma K; Sakurai Y
J Pharmacobiodyn; 1980 Oct; 3(10):532-6. PubMed ID: 6937651
[TBL] [Abstract][Full Text] [Related]
30. [Study of new antineoplastic antibiotics based on newly discovered action mechanisms].
Tanaka N
Gan To Kagaku Ryoho; 1983 Apr; 10(4 Pt 2):1094-106. PubMed ID: 6191673
[TBL] [Abstract][Full Text] [Related]
31. Chemical modification of anthracycline antibiotics. I. Demethoxycarbonylation, 10-epimerization and 4-o-methylation of aclacinomycin A.
Tanaka H; Yoshioka T; Shimauchi Y; Matsuzawa Y; Oki T; Inui T
J Antibiot (Tokyo); 1980 Nov; 33(11):1323-30. PubMed ID: 6941951
[TBL] [Abstract][Full Text] [Related]
32. [Studies on the mechanism of drug resistance in tumor cells and a new antitumor antibiotic].
Tanaka N
Gan To Kagaku Ryoho; 1984 Dec; 11(12 Pt 2):2666-73. PubMed ID: 6210060
[TBL] [Abstract][Full Text] [Related]
33. [Antitumor activity of macromomycin].
Kato T; Yamanaka N; Katayama S; Mizutani M; Ota K
Gan To Kagaku Ryoho; 1982 Jul; 9(6):1097-101. PubMed ID: 7184442
[TBL] [Abstract][Full Text] [Related]
34. Phase I and pharmacokinetic study of high volume intraperitoneal aclacinomycin-A (Aclarubicin).
Kerr IG; Archer S; DeAngelis C; Farrell S; Hanna S; McKee J
Invest New Drugs; 1987; 5(2):171-6. PubMed ID: 3477533
[TBL] [Abstract][Full Text] [Related]
35. Experimental and clinical studies on aclarubicin in the treatment of solid tumors.
Kumai K; Kubota T; Ishibiki K; Abe O
Biomed Pharmacother; 1984; 38(7):332-7. PubMed ID: 6596963
[TBL] [Abstract][Full Text] [Related]
36. Chemical modification of anthracycline antibiotics. V. Synthesis of 2-hydroxyaclacinomycin A by chemical glycosidation.
Tanaka H; Yoshioka T; Yoshimoto A; Shimauchi Y; Ishikura T; Takeuchi T; Umezawa H
J Antibiot (Tokyo); 1983 May; 36(5):601-3. PubMed ID: 6874576
[No Abstract] [Full Text] [Related]
37. Phase II trial of aclacinomycin in acute leukemia and lymphosarcoma.
Mathé G; Gil MA; Delgado M; Bayssas M; Gouveia J; Ribaud P; Machover D; Misset JL; de Vassal F; Schwarzenberg L; Jasmin C; Hayat M
Recent Results Cancer Res; 1980; 74():217-22. PubMed ID: 6893752
[No Abstract] [Full Text] [Related]
38. Difference between the resistance mechanisms of aclacinomycin- and adriamycin-resistant P388 cell lines.
Dong J; Naito M; Tatsuta T; Seimiya H; Johdo O; Tsuruo T
Oncol Res; 1995; 7(5):245-52. PubMed ID: 8534930
[TBL] [Abstract][Full Text] [Related]
39. Aclacinomycin. Phase II evaluation in advanced squamous carcinoma of the head and neck.
Kish JA; Al-Sarraf M
Am J Clin Oncol; 1984 Oct; 7(5):535-7. PubMed ID: 6507374
[TBL] [Abstract][Full Text] [Related]
40. Induction of chromosomal aberrations by the anthracycline antitumor antibiotics N,N-dimethyldaunomycin and aclacinomycin A.
Steinheider G; Westendorf J; Marquardt H
Experientia; 1987 May; 43(5):586-8. PubMed ID: 3472901
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
